Company intelligence / Profile preview

Plumbline Life Sciences

Seoul, South Korea

Ownership: Private
Employees: ~28
Development stage: Other

Overview

Plumbline Life Sciences is a South Korean biopharmaceutical company focused on developing and commercializing DNA-based therapies and vaccines for animals. Its plasmid DNA platform is designed to deliver stable, potent, and safe DNA medicines, primarily for companion and farm animals, with several products already on the market and others in development or recently launched (e.g., Renudog for aging in dogs). The company is notable for its first-in-class DNA medicine for veterinary use and its partnerships in infectious disease prevention.

Therapeutic areas: NephrologyImmunologyInfectious DiseasesOtherOncology
Modalities: DNA vaccineDNA therapyPlasmid-based DNA deliveryGene therapy
Industry: Veterinary

Partnerships

Inovio Pharmaceuticals

Beyond the preview

Go deeper on Plumbline Life Sciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Plumbline Life Sciences.

Explore the full profile